Major Investor Group Converts Preferred Stock to Common, Securing Majority Ownership

summarizeSummary

A major investor group, including Artal and Invus entities, converted preferred stock into over 20 million common shares, resulting in collective beneficial ownership of 51.1% of Lexicon Pharmaceuticals.

check_boxKey Events · Ownership and Investor Activity · LXRX

• Preferred Stock Conversion Completed

  On April 30, 2026, Artal Participations S.a r.l. converted 408,434.70 shares of Preferred Stock into 20,421,735 shares of Lexicon's common stock, following the satisfaction of all conversion conditions.

• Investor Group Achieves Majority Ownership

  The reporting persons, including Artal and Invus entities, now collectively beneficially own 227,034,705 shares, representing approximately 51.1% of the outstanding common stock.

• Significant Capital Commitment Solidified

  This conversion finalizes a prior investment, with the preferred stock initially purchased at $65.00 per share, equivalent to $1.30 per common share, demonstrating a substantial long-term commitment from the investor group.

auto_awesomeAnalysis · LXRX · Life Sciences

This Schedule 13D/A reports the conversion of preferred stock held by Artal Participations S.a r.l. into common stock, a significant event that solidifies the control of a major investor group. The conversion of over 20 million shares of common stock, valued at approximately $40 million based on the current stock price, results in the reporting persons collectively owning over 51% of Lexicon's outstanding shares. This deepens the commitment of a key investor during a period of positive momentum for the company, following recent news of a new loan facility and improved first-quarter financial results. The conversion, which occurred when the stock was trading near its 52-week high, indicates a favorable outcome for the investor group who acquired the preferred stock at an effective common share price of $1.30.